CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Lauren Giuffrida(The University of Melbourne), Paul A. Beavis(Peter MacCallum Cancer Centre), Melissa A. Henderson(The University of Melbourne), Gregory D. Stewart(Monash University), Emma V. Petley(The University of Melbourne), Paul J. Neeson(The University of Melbourne), Kirsten L. Todd(The University of Melbourne), Junyun Lai(The University of Melbourne), Déborah Meyran(The University of Melbourne), Benjamin Solomon(Peter MacCallum Cancer Centre), Phillip K. Darcy(Peter MacCallum Cancer Centre), Lev M. Kats(Beth Israel Deaconess Medical Center), Kevin Sek(The University of Melbourne), Imran G. House(The University of Melbourne), Christina Mølck(The University of Melbourne), Amanda X. Y. Chen(Peter MacCallum Cancer Centre), Sherly Mardiana(The University of Melbourne), Simon J. Harrison(Peter MacCallum Cancer Centre), Ian A. Parish(The University of Melbourne)
Cited by 206
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835